Efficacy and safety of belimumab given for 12 months in primary Sjögren’s syndrome: the BELISS open-label phase II study
Salvatore De Vita
◽
Luca Quartuccio
◽
Raphaèle Seror
◽
Sara Salvin
◽
Philippe Ravaud
◽
...
2015 ◽
Vol 74
(Suppl 2)
◽
pp. 338.3-339
◽
S. De Vita
◽
L. Quartuccio
◽
R. Seror
◽
S. Salvin
◽
P. Ravaud
◽
...
2013 ◽
Vol 74
(3)
◽
pp. 526-531
◽
Xavier Mariette
◽
Raphaèle Seror
◽
Luca Quartuccio
◽
Gabriel Baron
◽
Sara Salvin
◽
...
2005 ◽
Vol 52
(9)
◽
pp. 2740-2750
◽
J. Pijpe
◽
G. W. van Imhoff
◽
F. K. L. Spijkervet
◽
J. L. N. Roodenburg
◽
G. J. Wolbink
◽
...
2013 ◽
Vol 72
(Suppl 3)
◽
pp. A89.2-A89
◽
P. Meiners
◽
A. Vissink
◽
F. Kroese
◽
F. Spijkervet
◽
E. Haacke
◽
...
2018 ◽
Vol 38
(2)
◽
pp. 617-618
Xia Liu
◽
Xiaomei Li
◽
Xiangpei Li
◽
Zhijun Li
◽
Dongbao Zhao
◽
...
2013 ◽
Vol 65
(4)
◽
pp. 1097-1106
◽
E. William St.Clair
◽
Marc C. Levesque
◽
Eline T. Luning Prak
◽
Frederick B. Vivino
◽
Chacko J. Alappatt
◽
...
2018 ◽
Vol 85
(1)
◽
pp. 15-22
◽
Hind Letaief
◽
Cédric Lukas
◽
Thomas Barnetche
◽
Cécile Gaujoux-Viala
◽
Bernard Combe
◽
...
2019 ◽
Vol 28
(3)
◽
pp. 370-378
◽
Min-Ji Kang
◽
Youn-Hee Kim
◽
Miyoung Chou
◽
Jehyung Hwang
◽
Eun-Jeong Cheon
◽
...
2007 ◽
Vol 66
(8)
◽
pp. 1026-1032
◽
J M van Woerkom
◽
A A Kruize
◽
R Geenen
◽
E N van Roon
◽
R Goldschmeding
◽
...